Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bexion Pharma has received $1.5m Phase II Small Business Innovation Research (SBIR) grant for a two year period from the National Cancer Institute (NCI).
Subscribe to our email newsletter
Bexion Pharma has received the Phase II SBIR grant to identify and select optimised SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion’s drug toward planned human testing.
NCI has previously selected Bexion for a notable research collaboration with its Nanotechnology Characterisation Laboratory (NCL), a part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology.
Bexion claimed that its proprietary technology is based on Saposin C- dioleoylphosphatidylserine (dubbed ‘SapC-DOPS’) and is a nanovesicle therapeutic for the treatment of glioblastomas (GBM), pancreatic cancers and other solid tumors.
Bexion co-founder and CEO Ray Takigiku said that the Phase II award will expedite their goal to develop a new molecular entity with a new mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma).